171 related articles for article (PubMed ID: 17867646)
1. Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry.
Yukinaga H; Takami T; Shioyama SH; Tozuka Z; Masumoto H; Okazaki O; Sudo K
Chem Res Toxicol; 2007 Oct; 20(10):1373-8. PubMed ID: 17867646
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation.
Baer BR; Wienkers LC; Rock DA
Chem Res Toxicol; 2007 Jun; 20(6):954-64. PubMed ID: 17497897
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.
Chen Q; Ngui JS; Doss GA; Wang RW; Cai X; DiNinno FP; Blizzard TA; Hammond ML; Stearns RA; Evans DC; Baillie TA; Tang W
Chem Res Toxicol; 2002 Jul; 15(7):907-14. PubMed ID: 12119000
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.
Lightning LK; Jones JP; Friedberg T; Pritchard MP; Shou M; Rushmore TH; Trager WF
Biochemistry; 2000 Apr; 39(15):4276-87. PubMed ID: 10757976
[TBL] [Abstract][Full Text] [Related]
6. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates.
Pearson JT; Wahlstrom JL; Dickmann LJ; Kumar S; Halpert JR; Wienkers LC; Foti RS; Rock DA
Chem Res Toxicol; 2007 Dec; 20(12):1778-86. PubMed ID: 18001057
[TBL] [Abstract][Full Text] [Related]
7. Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.
Kent UM; Lin HL; Mills DE; Regal KA; Hollenberg PF
Chem Res Toxicol; 2006 Feb; 19(2):279-87. PubMed ID: 16485904
[TBL] [Abstract][Full Text] [Related]
8. Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry.
Bateman KP; Baker J; Wilke M; Lee J; Leriche T; Seto C; Day S; Chauret N; Ouellet M; Nicoll-Griffith DA
Chem Res Toxicol; 2004 Oct; 17(10):1356-61. PubMed ID: 15487896
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent photoaffinity labeling of cytochrome P450 3A4 by lapachenole: identification of modification sites by mass spectrometry.
Wen B; Doneanu CE; Gartner CA; Roberts AG; Atkins WM; Nelson SD
Biochemistry; 2005 Feb; 44(6):1833-45. PubMed ID: 15697209
[TBL] [Abstract][Full Text] [Related]
10. Elucidation of distinct ligand binding sites for cytochrome P450 3A4.
Hosea NA; Miller GP; Guengerich FP
Biochemistry; 2000 May; 39(20):5929-39. PubMed ID: 10821664
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
12. Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4.
He K; Bornheim LM; Falick AM; Maltby D; Yin H; Correia MA
Biochemistry; 1998 Dec; 37(50):17448-57. PubMed ID: 9860860
[TBL] [Abstract][Full Text] [Related]
13. Photochromic agents as tools for protein structure study: lapachenole is a photoaffinity ligand of cytochrome P450 3A4.
Gartner CA; Wen B; Wan J; Becker RS; Jones G; Gygi SP; Nelson SD
Biochemistry; 2005 Feb; 44(6):1846-55. PubMed ID: 15697210
[TBL] [Abstract][Full Text] [Related]
14. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2005 Apr; 313(1):154-64. PubMed ID: 15608076
[TBL] [Abstract][Full Text] [Related]
15. Bioactivation of the cannabinoid receptor antagonist rimonabant to a cytotoxic iminium ion metabolite.
Foster AJ; Prime LH; Gustafsson F; Temesi DG; Isin EM; Midlöv J; Castagnoli N; Kenna JG
Chem Res Toxicol; 2013 Jan; 26(1):124-35. PubMed ID: 23234359
[TBL] [Abstract][Full Text] [Related]
16. Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity.
Moore CD; Shahrokh K; Sontum SF; Cheatham TE; Yost GS
Biochemistry; 2010 Oct; 49(41):9011-9. PubMed ID: 20812728
[TBL] [Abstract][Full Text] [Related]
17. The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein.
Lin HL; Hollenberg PF
J Pharmacol Exp Ther; 2007 Apr; 321(1):276-87. PubMed ID: 17251390
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
Tang LWT; Verma RK; Fan H; Chan ECY
Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
[TBL] [Abstract][Full Text] [Related]
19. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.
Lin HL; Zhang H; Medower C; Hollenberg PF; Johnson WW
Drug Metab Dispos; 2011 Feb; 39(2):345-50. PubMed ID: 21068193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
